Last reviewed · How we verify
Shanghai Proton and Heavy Ion Center — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Conventional chemotherapy | Conventional chemotherapy | marketed | ||||
| Maintenance chemotherapy 2 | Maintenance chemotherapy 2 | phase 3 | Oncology | |||
| Maintenance chemotherapy 1 | Maintenance chemotherapy 1 | phase 3 | Oncology |
Therapeutic area mix
- Oncology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Shanghai Proton and Heavy Ion Center:
- Shanghai Proton and Heavy Ion Center pipeline updates — RSS
- Shanghai Proton and Heavy Ion Center pipeline updates — Atom
- Shanghai Proton and Heavy Ion Center pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shanghai Proton and Heavy Ion Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-proton-and-heavy-ion-center. Accessed 2026-05-17.